Ankylosing Spondylitis Market Across 7 Key Regions Projected to Hit USD 10.2 Billion by 2035

The ankylosing spondylitis market reached a value of USD 5.1 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 10.2 Billion by 2035, exhibiting a growth rate (CAGR) of 6.53% during 2025-2035.

Significant advancements in treatment options, increased awareness, and improvement in diagnostic capabilities is contributing to the growth of the ankylosing spondylitis (AS) market in 2025. Research and development activities focused on improving the outcomes and quality of life for patients suffering with AS, which is a chronic inflammatory disease primarily affecting the spine, has grown considerably in the recent past.

Evolution of therapeutic modalities remain distinctive in the AS market. Older methods like nonsteroidal anti-inflammatory drugs (NSAIDs) remain an integral part of treatment plans, but they have been joined by the use of biologic therapies which represent a paradigm shift in the management of the disease. Tumor necrosis factor (TNF) and interleukin - 17(IL-17) inhibitors have proven to be effective in controlling inflammation and slowing the progress of the disease. Treatment options for patients have widened further with the introduction of biosimilars which are economic alternatives to established biologics.

The field of tailored therapies is emerging in the AS market. Genetic and molecular advancements allow development of treatment strategies suitable for specific patients which aims to maximize the efficiency of intervention while reducing negative consequences. This shift underscores a move towards treating patients as individuals rather than statistics.

Based on the demographic factors of population distribution, North America continues to lead the AS market given its developed healthcare system and high disease prevalence. Associated States is a major contributor owing to high share from increased diagnosis and treatment accessibility . Europe comes afterward, with Germany at the forefront owing to strong healthcare systems and considerable R&D expenditure .

The region is set to be one of the leading spot with the rise of awareness, better access to healthcare resources, and new therapies being introduced. China and India are now more frequently diagnosed and are in the process of developing their healthcare system to address the AS treatment needs .

Regardless of these factors, there are still some issues. Adoption of treatment, especially for low and middle-income countries, is limited by the high cost of biologic therapies. This is being worked on with the creation and marketing of biosimilars that aim to provide affordable options without clinical effectiveness .

Request for a sample of this report: https://www.imarcgroup.com/ankylosing-spondylitis-market/requestsample

Time Period of the Study

Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the ankylosing spondylitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the ankylosing spondylitis market
Reimbursement scenario in the market
In-market and pipeline drugs

Buy Full Report @ https://www.imarcgroup.com/checkout?id=6766&method=809

Competitive Landscape:

This report also provides a detailed analysis of the current ankylosing spondylitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

IMARC Group Offers Other Reports:

Rheumatoid arthritis market https://www.imarcgroup.com/rheumatoid-arthritis-market

Schizophrenia market
https://www.imarcgroup.com/schizophrenia-market

Scoliosis market https://www.imarcgroup.com/scoliosis-market

Smoking cessation market https://www.imarcgroup.com/smoking-cessation-market

Stargardt disease market https://www.imarcgroup.com/stargardt-disease-market

Vertigo market https://www.imarcgroup.com/vertigo-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.